ARK Genomic Revolution ETF Up on 3.4% Tempus AI Surge After HRD-RNA Launch
ARK Genomic Revolution ETF holds 8.63% of its assets in Tempus AI, which rose 3.41% to $54.35 premarket following the launch of its HRD-RNA algorithm for HRD detection in tumors. The real-world study showed HRD-RNA positive metastatic pancreatic cancer patients saw significantly reduced mortality risk on platinum regimens.
1. ARKG Exposure to Tempus AI
ARK Genomic Revolution ETF allocates 8.63% of its portfolio to Tempus AI, making TEM a key driver of ARKG’s net asset value. Significant moves in TEM’s share price can materially influence the ETF’s overall performance given its substantial weighting.
2. TEM’s HRD-RNA Algorithm Details
Tempus AI introduced HRD-RNA, an AI tool analyzing the transcriptome to detect homologous recombination deficiency. In a real-world study, metastatic pancreatic cancer patients identified as HRD-RNA positive experienced a notable reduction in mortality risk when treated with first-line platinum regimens.
3. Stock Performance and Technical Indicators
Tempus AI shares gained 3.41% to $54.35 in premarket trading and remain 8.3% below their 20-day simple moving average. With an RSI of 35.5 in neutral territory and a MACD still below its signal line, the trend signals mixed momentum and potential near-term volatility.
4. Implications for ARKG
Innovative developments in portfolio companies like Tempus AI can attract inflows into thematic funds such as ARKG. The planned clinical availability of HRD-RNA later this year could serve as an additional catalyst, potentially offsetting broader market headwinds for the ETF.